本帖最后由 老马 于 2013-3-13 13:43 编辑
% ?. C. }4 K& p, m1 o
4 i! {* |2 S% W/ \% H健择（吉西他滨）+顺铂+阿瓦斯汀/ I1 n& ~; p: l0 X) l
Gemzar +Cisplatin + Avastin
7 ]9 G4 `% N0 D% g6 ^# ]http://annonc.oxfordjournals.org/content/21/9/1804.full) y. R( h7 W; z: q6 `
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ! F- F0 z2 L1 a& Y1 B( w% c8 ^
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ D$ c! m1 y$ b! t8 E) c0 xResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 _: }& ~9 a% U# x% H
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 973)
6 F- n% a/ c; f. a; b华为网盘附件：+ ]" K* ^$ k+ ^& y# V
【华为网盘】ava.JPG: {5 c, h/ b: g9 w" ?* O: [
|
显身卡
